AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2806735 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistance training using modified computer games for the first six months.
Number of subjects: 0
Study 2806735 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory resistance training using modified computer games for the second six months.
Number of subjects: 0
Study 31035354 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-fortified diet (1.8 g/kg/day)
Number of subjects: 40
Study 31035354 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 40
Study 28559408 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigators included in support networks
Number of subjects: 25
Study 28559408 — intervention group
Group type: COMPARATOR
Intervention: Networks without a navigator
Number of subjects: 25
Study 28559408 — intervention group
Group type: COMPARATOR
Intervention: Network metrics
Number of subjects: 25
Study 26317839 — intervention group
Group type: EXPERIMENTAL
Intervention: Aftercare with telephone intervention
Number of subjects: 600
Study 26317839 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 600
Study 24043732 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab
Number of subjects: 0
Study 24043732 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 21741011 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine co-administered with hepatitis B vaccine
Number of subjects: 70
Study 19352043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystine/Theanine (CT)
Number of subjects: 15
Study 19352043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17075318 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1500 mg/m) as a 30‐min intravenous infusion on days 1 and 8, followed by oxaliplatin (130 mg/m) as a 4‐h intravenous infusion on day 8 every 21 days
Number of subjects: 10
Study 17075318 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (without oxaliplatin coadministration) on day 1
Number of subjects: 10
Study 15523163 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cleaning with 66% ethyl alcohol (Group B)
Number of subjects: 100
Study 15523163 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cleaning with 66% ethyl alcohol (Group D)
Number of subjects: 100
Study 15523163 — intervention group
Group type: COMPARATOR
Intervention: No cleaning (Group C)
Number of subjects: 100
Study 11079436 — intervention group
Group type: EXPERIMENTAL
Intervention: Television series 'Families'
Number of subjects: 56
Study 11079436 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 56
Study 10072831 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) at a dose of 200 micrograms.d‐1 for 5 days
Number of subjects: 30
Study 10072831 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGE1)
Number of subjects: 30
Study 7691117 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 with G-CSF
Number of subjects: 18
Study 7691117 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/m2 with G-CSF
Number of subjects: 18
Study 7691117 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 60 mg/m2 without G-CSF
Number of subjects: 18
Study 6818829 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol with digital ocular compression
Number of subjects: 59
Study 6818829 — intervention group
Group type: COMPARATOR
Intervention: Combined acetazolamide-mannitol pre-medication with digital compression
Number of subjects: 59
Study 31244398 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world news coverage
Number of subjects: 321
Study 31244398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical news coverage following CDC recommendations
Number of subjects: 321
Study 31244398 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypothetical coverage not specified)
Number of subjects: 321
Study 29185930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sourdough-fermented rye crispbread
Number of subjects: 24
Study 29185930 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfermented rye crispbread
Number of subjects: 24
Study 29185930 — intervention group
Group type: COMPARATOR
Intervention: Yeast-fermented refined wheat crispbread
Number of subjects: 24
Study 25394692 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus omega-3 supplementation (900 mg/day orally)
Number of subjects: 87
Study 25394692 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (control)
Number of subjects: 87
Study 25764643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative periarticular injection with multimodal drugs (diclofenac, adrenaline, marcaine, morphine)
Number of subjects: 42
Study 25764643 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 42
Study 25764643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 22292592 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight aluminum cylinders (3.6-lb)
Number of subjects: 22
Study 22292592 — intervention group
Group type: COMPARATOR
Intervention: E-cylinders (22-lb)
Number of subjects: 22
Study 22292592 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (lightweight and E-cylinders)
Number of subjects: 22
Study 19766534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir for 6 weeks
Number of subjects: 100
Study 19766534 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 100
Study 17323791 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 microg twice daily (BID)
Number of subjects: 180
Study 17323791 — intervention group
Group type: COMPARATOR
Intervention: Placebo BID
Number of subjects: 180
Study 17129838 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam 2.250 g
Number of subjects: 501
Study 17129838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study 12589281 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (silicone index)
Number of subjects: 30
Study 12589281 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (depth gauge bur)
Number of subjects: 30
Study 12589281 — intervention group
Group type: COMPARATOR
Intervention: Group A (control, freehand approach)
Number of subjects: 30
Study 10589314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-visited
Number of subjects: 480
Study 10589314 — intervention group
Group type: COMPARATOR
Intervention: Paraprofessional-visited
Number of subjects: 480
Study 7805916 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular fluid (FF)
Number of subjects: 46
Study 7805916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixtures of peritoneal fluid (PF) and follicular fluid (FF)
Number of subjects: 46
Study 7805916 — intervention group
Group type: COMPARATOR
Intervention: Earle's medium (control)
Number of subjects: 46
Study 7805916 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid (PF) alone
Number of subjects: 46
Study 1826962 — intervention group
Group type: EXPERIMENTAL
Intervention: etanidazole (2.0 g/m2) and pimonidazole (0.75 g/m2)
Number of subjects: 48
Study 1826962 — intervention group
Group type: EXPERIMENTAL
Intervention: etanidazole (2.0 g/m2/dose) and pimonidazole (0.75 g/m2)
Number of subjects: 48
Study 6761288 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine/caffeine
Number of subjects: 201
Study 6761288 — intervention group
Group type: COMPARATOR
Intervention: Mazindol
Number of subjects: 201
Study 6761288 — intervention group
Group type: COMPARATOR
Intervention: Diethylpropion
Number of subjects: 201
Study 31483273 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiosk system
Number of subjects: 46
Study 31483273 — intervention group
Group type: COMPARATOR
Intervention: Smartphone-based app
Number of subjects: 46
Study 27993828 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 50 mg
Number of subjects: 283
Study 27993828 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 283
Study 27993828 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 283
Study 27993828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 26256300 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol supplementation in cardioplegia (6 μg/mL)
Number of subjects: 101
Study 26256300 — intervention group
Group type: COMPARATOR
Intervention: Intralipid (placebo)
Number of subjects: 101
Study 23721577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec varnish
Number of subjects: 50
Study 23721577 — intervention group
Group type: COMPARATOR
Intervention: Duraphat varnish
Number of subjects: 50
Study 21704239 — intervention group
Group type: EXPERIMENTAL
Intervention: CER 30 mg once daily
Number of subjects: 36
Study 21704239 — intervention group
Group type: COMPARATOR
Intervention: CIR 10 mg TID
Number of subjects: 36
Study 19319076 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study 19319076 — intervention group
Group type: COMPARATOR
Intervention: Control (no propranolol)
Number of subjects: 20
Study 17041518 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuracryl M embolization
Number of subjects: 6
Study 12616370 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision and marsupialization with dressing by bacterial collagenase
Number of subjects: 40
Study 12616370 — intervention group
Group type: COMPARATOR
Intervention: Excision and marsupialization without dressing by bacterial collagenase
Number of subjects: 40
Study 11060533 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal metabolic bone disease (evidence of high peak plasma alkaline phosphatase >1200 IU)
Number of subjects: 765
Study 11060533 — intervention group
Group type: EXPERIMENTAL
Intervention: Height at 9 to 12 years
Number of subjects: 765
Study 11060533 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental height and pubertal status
Number of subjects: 765
Study 9360702 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant vaccine against hepatitis B virus (HBV)
Number of subjects: 103
Study 1592065 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (Caf) 250 mg
Number of subjects: 14
Study 1592065 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 14
Study 3881177 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 88
Study 31466614 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study 31466614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 29750365 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated medical therapy
Number of subjects: 259
Study 29750365 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 259
Study 29750365 — intervention group
Group type: COMPARATOR
Intervention: Prior coronary revascularization
Number of subjects: 259
Study 29750365 — intervention group
Group type: COMPARATOR
Intervention: Non-revascularized patients
Number of subjects: 259
Study 26739248 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study 26739248 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 26739248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25042877 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic orchiopexy
Number of subjects: 46
Study 25042877 — intervention group
Group type: COMPARATOR
Intervention: Open orchiopexy
Number of subjects: 46
Study 22910324 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 85
Study 22910324 — intervention group
Group type: COMPARATOR
Intervention: ABC/3TC
Number of subjects: 85
Study 20575654 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural progesterone (NP) per vagina at 100 mg/day
Number of subjects: 100
Study 20575654 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural progesterone (NP) per vagina at 200 mg/day
Number of subjects: 100
Study 20575654 — intervention group
Group type: COMPARATOR
Intervention: Natural progesterone (NP) per os at 100 mg/day
Number of subjects: 100
Study 20575654 — intervention group
Group type: COMPARATOR
Intervention: Natural progesterone (NP) per os at 200 mg/day
Number of subjects: 100
Study 17661579 — intervention group
Group type: EXPERIMENTAL
Intervention: Right breast pumping
Number of subjects: 35
Study 17661579 — intervention group
Group type: EXPERIMENTAL
Intervention: Left breast pumping
Number of subjects: 35
Study 17661579 — intervention group
Group type: EXPERIMENTAL
Intervention: Both breasts pumping
Number of subjects: 35
Study 16547380 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard amino acid solution with glutamine dipeptide (20% of total amino acids)
Number of subjects: 55
Study 16547380 — intervention group
Group type: COMPARATOR
Intervention: Standard amino acid solution
Number of subjects: 55
Study 11465341 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone replacement (1 to 2 U GH/day) for 6 months, followed by 2 U GH/day for an additional 6 months.
Number of subjects: 24
Study 10195069 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (18 micrograms)
Number of subjects: 16
Study 10195069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7723001 — intervention group
Group type: EXPERIMENTAL
Intervention: Urn randomization
Number of subjects: 0
Study 3395542 — intervention group
Group type: EXPERIMENTAL
Intervention: MST 60 mg
Number of subjects: 61
Study 3395542 — intervention group
Group type: EXPERIMENTAL
Intervention: MST 60 mg and diazepam 10 mg
Number of subjects: 61
Study 3395542 — intervention group
Group type: EXPERIMENTAL
Intervention: MST 60 mg and hyoscine 0.6 mg
Number of subjects: 61
Study 3395542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 29145527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral scanning (IOS)
Number of subjects: 19
Study 29145527 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression (CI) taking
Number of subjects: 19
Study 28617566 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 3,000 mg daily
Number of subjects: 40
Study 28617566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28617566 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 40
Study 26069941 — intervention group
Group type: COMPARATOR
Intervention: Insemination
Number of subjects: 25
Study 26069941 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced ovulation (750 IU eCG, 500 IU hCG)
Number of subjects: 25
Study 26069941 — intervention group
Group type: EXPERIMENTAL
Intervention: Superovulation (1,500 IU eCG, 1,000 IU hCG)
Number of subjects: 25
Study 22784488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerasul bearing
Number of subjects: 250
Study 22784488 — intervention group
Group type: COMPARATOR
Intervention: Metasul bearing
Number of subjects: 250
Study 22784488 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (Cerasul and Metasul)
Number of subjects: 250
Study 21527594 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral synbiotics (Bifidobacterium, Lactobacillus, and galactooligosaccharides) preoperatively for 14 days and postoperatively for 11 days
Number of subjects: 61
Study 21527594 — intervention group
Group type: COMPARATOR
Intervention: No synbiotics (control)
Number of subjects: 61
Study 21527594 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral synbiotics
Number of subjects: 61
Study 18467280 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with prophylactic EPO therapy
Number of subjects: 135
Study 18467280 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 135
Study 17518666 — intervention group
Group type: EXPERIMENTAL
Intervention: HYAFF p100 (total benzyl ester of hyaluronan)
Number of subjects: 20
Study 17518666 — intervention group
Group type: COMPARATOR
Intervention: HYAFF p80 (partial benzyl ester of hyaluronan)
Number of subjects: 20
Study 12953793 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of HCA
Number of subjects: 6
Study 12953793 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrin)
Number of subjects: 6
Study 10659113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (massage with Roman chamomile essential oil)
Number of subjects: 103
Study 10659113 — intervention group
Group type: COMPARATOR
Intervention: Massage (massage with carrier oil)
Number of subjects: 103
Study 8892452 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy total dose extended field radiotherapy (EF‐RT)
Number of subjects: 376
Study 8892452 — intervention group
Group type: COMPARATOR
Intervention: 30 Gy total dose extended field radiotherapy (EF‐RT) plus 10 Gy total dose involved field radiotherapy (IF‐RT)
Number of subjects: 376
Study 1985011 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal (Ensure Plus)
Number of subjects: 20
Study 1985011 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 mg/SL)
Number of subjects: 20
Study 1985011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6607819 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg once daily
Number of subjects: 45
Study 6607819 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 250 mg twice daily
Number of subjects: 45
Study 29776112 — intervention group
Group type: EXPERIMENTAL
Intervention: Tensor renormalization group algorithm with randomized singular value decomposition; specific details on dosage and duration not applicable.
Number of subjects: 0
Study 29776112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oversampling parameter larger than the bond dimension; specific details on dosage and duration not applicable.
Number of subjects: 0
Study 26836950 — intervention group
Group type: EXPERIMENTAL
Intervention: Quisinostat 12 mg three times weekly
Number of subjects: 26
Study 24035407 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (target dose 24 mg)
Number of subjects: 100
Study 24035407 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (target dose 1.5 mg)
Number of subjects: 100
Study 22911284 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Exercise Program (GI) - strength, balance, and functional mobility exercises, 50 minutes, twice a week for 4 months
Number of subjects: 36
Study 22911284 — intervention group
Group type: COMPARATOR
Intervention: Stretching Exercises (GC) - 50 minutes, twice a week for 4 months
Number of subjects: 36
Study 22911284 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between handgrip strength test and bone mineral density (BMD) of the femoral neck
Number of subjects: 36
Study 22911284 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between handgrip strength test and BMD of the total femur
Number of subjects: 36
Study 20856886 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in plasma HIV-1 RNA by 0.74 log(10) copies/mL
Number of subjects: 3381
Study 20856886 — intervention group
Group type: COMPARATOR
Intervention: Baseline plasma HIV-1 levels ≥4 log(10) copies/mL
Number of subjects: 3381
Study 18074146 — intervention group
Group type: EXPERIMENTAL
Intervention: Exponential rebreathing method
Number of subjects: 18
Study 18074146 — intervention group
Group type: COMPARATOR
Intervention: Equilibrium rebreathing method
Number of subjects: 18
Study 18074146 — intervention group
Group type: COMPARATOR
Intervention: Inert gas rebreathing method
Number of subjects: 18
Study 16170715 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidetector-row CT (MDCT)
Number of subjects: 59
Study 16170715 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pyelography (IVP)
Number of subjects: 59
Study 16170715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined unenhanced and excretory phase MDCT
Number of subjects: 59
Study 12690415 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-lipiodol therapy with a mean activity of 1.9 GBq (SD 0.2)
Number of subjects: 15
Study 12690415 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-lipiodol therapy with potassium iodide (KI) thyroid blocking
Number of subjects: 15
Study 12690415 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological dosimetry using the in vitro micronucleus (MN) assay
Number of subjects: 15
Study 12690415 — intervention group
Group type: EXPERIMENTAL
Intervention: MCNP method for dosimetry
Number of subjects: 15
Study 12690415 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRDOSE method for dosimetry
Number of subjects: 15
Study 12690415 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient dosimetry
Number of subjects: 15
Study 10479839 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical tracheostomy (n = 25)
Number of subjects: 50
Study 10479839 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy (n = 25)
Number of subjects: 50
Study 8946272 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg dexfenfluramine twice daily
Number of subjects: 52
Study 8946272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 2014076 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) 3‐mg pessaries 4 hours apart, followed by oxytocin infusion if necessary
Number of subjects: 94
Study 2014076 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin infusion
Number of subjects: 94
Study 2014076 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 94
Study 7171536 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of breakfast
Number of subjects: 0
Study 7171536 — intervention group
Group type: COMPARATOR
Intervention: Omission of breakfast
Number of subjects: 0
Study 6368424 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rifampin (RMP) 600 mg and ethionamide (ETH) 500 mg
Number of subjects: 596
Study 6368424 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP administered twice a week for three months
Number of subjects: 596
Study 6368424 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP + ETH
Number of subjects: 596
Study 6368424 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of ETH and DDS or CLO
Number of subjects: 596
Study 6368424 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of daily dose of ETH or reduction of duration of RMP + ETH
Number of subjects: 596